Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies

Several studies have confirmed α-synuclein real-time quaking-induced conversion (αSyn-RT-QuIC) assay to have high sensitivity and specificity for Parkinson’s disease. However, whether the assay can be used as a robust, quantitative measure to monitor disease progression, stratify different synuclein...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Poggiolini, I, Gupta, V, Lawton, M, Lee, S, El-Turabi, A, Querejeta-Coma, A, Trenkwalder, C, Sixel-Döring, F, Foubert-Samier, A, Le Traon, AP, Plazzi, G, Biscarini, F, Montplaisir, J, Gagnon, J-F, Postuma, RB, Antelmi, E, Meissner, WG, Mollenhauer, B, Ben-Shlomo, Y, Hu, MT, Parkkinen, L
Natura:	Journal article
Lingua:	English
Pubblicazione:	Oxford University Press 2021

Documenti analoghi

Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies
di: Parkkinen, L, et al.
Pubblicazione: (2016)

Investigating brain-derived α-synuclein fibrils and diagnostic biomarkers of synucleinopathies
di: Lee, S
Pubblicazione: (2023)

LRP10 in α-synucleinopathies
di: Guerreiro, R, et al.
Pubblicazione: (2018)

LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder
di: Ouled Amar Bencheikh, B, et al.
Pubblicazione: (2018)

Selective vulnerability in α-synucleinopathies.
di: Alegre-Abarrategui, J, et al.
Pubblicazione: (2019)

The link between neuroinflammation and the neurovascular unit in synucleinopathies
di: Wang, Qing, et al.
Pubblicazione: (2023)

Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson's disease
di: Ruffmann, C, et al.
Pubblicazione: (2018)

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
di: Parkkinen, L, et al.
Pubblicazione: (2004)

Unfolded protein response markers Grp78 and eIF2alpha are upregulated with increasing alpha‐synuclein levels in Lewy body disease
di: Hrabos, D, et al.
Pubblicazione: (2024)

Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy
di: Sarkar, Souvarish, et al.
Pubblicazione: (2021)

Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy
di: Sarkar, Souvarish, et al.
Pubblicazione: (2022)

Gut feelings about α-synuclein in gastrointestinal biopsies: biomarker in the making?
di: Ruffmann, C, et al.
Pubblicazione: (2016)

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance
di: Parkkinen, L, et al.
Pubblicazione: (2008)

From mechanisms to future therapy: a synopsis of isolated REM sleep behavior disorder as early synuclein-related disease
di: Stefani, A, et al.
Pubblicazione: (2025)

Gut feeling about alpha-synuclein in gastro-intestinal biopsies: biomarker in the making?
di: Ruffmann, C, et al.
Pubblicazione: (2015)

Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease
di: Parkkinen, L, et al.
Pubblicazione: (2003)

Can olfactory bulb biopsy be justified for the diagnosis of Parkinson’s disease? Comments on “olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders”
di: Parkkinen, L, et al.
Pubblicazione: (2008)

Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject
di: Parkkinen, L, et al.
Pubblicazione: (2005)

Relationship of Apolipoprotein E to Parkinson's disease-related alpha-synuclein pathology
di: Parkkinen, L, et al.
Pubblicazione: (2013)

Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms
di: Parkkinen, L, et al.
Pubblicazione: (2007)

Assessment of α-Synuclein Pathology
di: Alafuzoff, I, et al.
Pubblicazione: (2008)

Colonic mucosal -synuclein lacks specificity as a biomarker for Parkinson disease
di: Ruffmann, C, et al.
Pubblicazione: (2015)

Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles
di: Doucet, M, et al.
Pubblicazione: (2017)

Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
di: Tapiola, T, et al.
Pubblicazione: (2009)

The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia
di: Compta, Y, et al.
Pubblicazione: (2013)

α-synuclein genetic variability: A biomarker for dementia in Parkinson disease
di: Guella, I, et al.
Pubblicazione: (2016)

Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders
di: Altay, MF, et al.
Pubblicazione: (2022)

Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2
di: Liekniņa, I, et al.
Pubblicazione: (2024)

Alpha-synuclein proximity ligation assay (AS-PLA) in brain sections to probe for alpha-synuclein oligomers
di: Roberts, RF, et al.
Pubblicazione: (2019)

Explaining the Structural Plasticity of α-Synuclein
di: Ullman, Orly, et al.
Pubblicazione: (2012)

Physiological and pathological properties of alpha-synuclein.
di: Tofaris, G, et al.
Pubblicazione: (2007)

Studying α-Synuclein pathology using iPSC-derived dopaminergic neurons
di: Zambon, F
Pubblicazione: (2017)

Molecular mechanisms of cerebrospinal fluid production.
di: Brown, P, et al.
Pubblicazione: (2004)

Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein.
di: Senior, S, et al.
Pubblicazione: (2008)

Upregulating β-hexosaminidase activity in rodents prevents α-synuclein lipid associations and protects dopaminergic neurons from α-synuclein-mediated neurotoxicity
di: Brekk, OR, et al.
Pubblicazione: (2020)

Optimisation of ExoCounter technology for use in cerebrospinal fluid and investigation of placenta-derived exosomes within cerebrospinal fluid
di: Davies, B
Pubblicazione: (2023)

Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages.
di: Haenseler, W, et al.
Pubblicazione: (2017)

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology
di: Vaikath, N, et al.
Pubblicazione: (2015)

α-Synuclein and dopamine at the crossroads of Parkinson's disease.
di: Venda, L, et al.
Pubblicazione: (2010)

Monitoring α-synuclein proteotoxicity in Drosophila models
di: Szabo, A, et al.
Pubblicazione: (2019)